Partnership will advance the field of ligand-based virtual screening to improve drug design and optimization activities

Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings

Investor Relations Contacts:

Lisa Fortuna
Financial Profiles
310-622-8251
slp@finprofiles.com

Renee Bouche
Simulations Plus Investor Relations
661-723-7723
renee.bouche@simulations-plus.com

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the award of a new research grant from the National Institutes of Health (NIH), secured in partnership with the University of Southern California (USC) Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences. The grant will be used to evaluate novel computational methods that account for water-ligand interactions in drug discovery and that integrate with the Artificial Intelligence-driven Drug Design (AIDD) module in ADMET Predictor^® to offer a first-of-its-kind ligand-based virtual screening (LBVS) solution for pharmaceutical companies.

For this award, Dr. Ian Haworth, Associate Professor and Vice Chair of Pharmacology and Pharmaceutical Sciences at the USC Mann School, and his lab will apply their previously developed algorithm (WATGEN) for the prediction of water positions in the unbound protein and protein-ligand complex. With support from the data scientists and software engineers at Simulations Plus, they will apply machine learning (ML) approaches to predict the pharmacophore features that will be used in ADMET Predictor’s proprietary 3D shape and feature matching algorithm.

“Identifying chemicals with shapes and characteristics similar to those that bind drug targets has been invaluable in drug discovery and development. However, the retention or displacement of water molecules during formation of the protein-ligand interface plays a significant role in determining ligand binding. This has often been overlooked in existing software programs, including LBVS algorithms,” said Dr. Noam Morningstar-Kywi, Scientist II at Simulations Plus and a key investigator for this grant. “Our goal is to develop new approaches that combine ML and validated 3D-based calculations to incorporate these essential water molecules into LBVS, enhancing current methods and enabling researchers to accelerate the discovery of better and more effective drugs.”

Dr. Haworth added, “We will harness the power of structure-based approaches, including the detailed information of protein-ligand and protein-water interactions, and combine them with the speed and accuracy associated with ligand-based similarity scoring methods. This project is a powerful collaboration between industry and academia that drives research from the lab into real-world applications, promising exciting, tangible results that could transform the field.”

The team at Simulations Plus will productize the updated methods into the ADMET Predictor platform and validate it by designing drugs against defined targets using the AIDD module. Selected compounds will be synthesized and tested experimentally to highlight the technology’s applications.

“As a drug discovery scientist, I am particularly excited to apply the NIH funding towards this innovative technology to design and test new compounds against several clinically relevant targets. We have the potential to dramatically reduce the Design-Make-Test-Analyze (DMTA) cycle of drug discovery,” said Dr. Jeremy Jones, Principal Scientist at Simulations Plus and principal investigator for this grant. “We are committed to driving impactful advancements that benefit our stakeholders and the global communities we serve, and we eagerly anticipate future collaborations that continue to create value and foster growth.”

The information presented in this press release is supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R43GM156103. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About the Haworth laboratory in the USC Mann School at the University of Southern California

Dr. Ian S. Haworth, a professor at USC, holds a PhD in physical organic chemistry from the University of Liverpool and conducted postdoctoral research at Oxford University. Since joining USC in 1992, his research has focused on the dynamics of molecular interactions of ligands with nucleic acids and proteins, combining chemistry, biology, and computational sciences. Dr. Haworth’s laboratory has developed innovative algorithms for nucleic acid structure building, molecular solvation, transporter protein analysis, and MHC-peptide-TCR association. His work, supported by federal and non-federal funding, has led to the publication of many papers in these areas.

About Simulations Plus, Inc.

With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | X | YouTube

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2023 ESG update.

Forward-Looking Statements

Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like “believe,” “expect,” and “anticipate” mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to successfully integrate the Pro-ficiency business with our own, as well as expenses we may incur in connection therewith, the efficiency and effectiveness of our internal business restructuring and leadership changes, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241008571649/en/